tradingkey.logo
tradingkey.logo
Suchen

Trinity Biotech PLC

TRIB
Zur Watchlist hinzufügen
0.377USD
+0.020+5.49%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
7.25MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Trinity Biotech PLC Unternehmen

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

Trinity Biotech PLC Informationen

BörsenkürzelTRIB
Name des UnternehmensTrinity Biotech PLC
IPO-datumOct 21, 1992
CEOGillard (John)
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
GeschäftsjahresendeOct 21
AddresseIda Business Park, Bray, Co Wicklow
StadtDUBLIN
BörseNASDAQ OMX - NASDAQ BASIC
LandIreland
Postleitzahl18
Telefon01135312955111
Websitehttps://www.trinitybiotech.com/
BörsenkürzelTRIB
IPO-datumOct 21, 1992
CEOGillard (John)

Führungskräfte von Trinity Biotech PLC

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Mr. Tom Lindsay
Mr. Tom Lindsay
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Colm Molloy
Mr. Colm Molloy
Group Director of Human Resources and Culture
Group Director of Human Resources and Culture
--
--
Mr. Eric Ribner
Mr. Eric Ribner
Investors Relations
Investors Relations
--
--
Mr. Andrew Omidvar, Ph.D.
Mr. Andrew Omidvar, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Mr. Tom Lindsay
Mr. Tom Lindsay
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Trinity Biotech PLC?

Die fünf größten Anteilseigner von Trinity Biotech PLC sind: Mr. Ronan O'caoimh

Wie viele Institutionen halten Anteile an Trinity Biotech PLC (TRIB)?

Mit Stand vom 2026Q1 halten 50 Institutionen Anteile an Trinity Biotech PLC, mit einem Gesamtmarktwert von etwa 876.37K, was 4.33% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -2074917.00 gestiegen.

Was ist die größte Einnahmequelle von Trinity Biotech PLC?

Am 2026Q1 erzielte das Geschäft mit Clinical Laboratory für Trinity Biotech PLC den höchsten Umsatz in Höhe von 42.29M, was 74.41% des Gesamtumsatzes entspricht.